BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10656450)

  • 1. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
    Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
    Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
    Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
    Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells.
    Donato NJ; Yan DH; Hung MC; Rosenblum MG
    Cell Growth Differ; 1993 May; 4(5):411-9. PubMed ID: 8518234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
    Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA; Mehmi I; Lupu R
    Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21WAF1.
    Xie W; Su K; Wang D; Paterson AJ; Kudlow JE
    Anticancer Res; 1997; 17(4A):2627-33. PubMed ID: 9252692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor.
    Perez M; Haschke B; Donato NJ
    Oncogene; 1999 Jan; 18(4):967-78. PubMed ID: 10023672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
    Huang S; Liu LN; Hosoi H; Dilling MB; Shikata T; Houghton PJ
    Cancer Res; 2001 Apr; 61(8):3373-81. PubMed ID: 11309295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis.
    Spierings DC; de Vries EG; Stel AJ; te Rietstap N; Vellenga E; de Jong S
    Oncogene; 2004 Jun; 23(28):4862-72. PubMed ID: 15122333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
    Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE
    Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
    Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
    Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
    Matheson SL; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
    Langton-Webster BC; Xuan JA; Brink JR; Salomon DS
    Cell Growth Differ; 1994 Dec; 5(12):1367-72. PubMed ID: 7696185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformation.
    Dolnikov A; Millington M; Sun LQ; Symonds G
    Cancer Gene Ther; 2000 Nov; 7(11):1491-503. PubMed ID: 11129291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog.
    Mujoo K; Watanabe M; Khokhar AR; Siddik ZH
    Prostate; 2005 Jan; 62(1):91-100. PubMed ID: 15389812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.